Skip to main content
MitoCore Biosciences

Educational research platform

Peptide research, traced to its sources

Explore public clinical, preclinical and regulatory research on peptides and related biologics. Every study links to its original source, evidence is graded by type, and approved uses are kept separate from investigational findings.

Explore ResearchBrowse Studies
  • Educational Only
  • Public Research
  • Safety First
  • Not Medical Advice

The research corpus

  • 445Indexed study recordsHuman, preclinical, regulatory and review sources
  • 45Peptide profilesIn the current public catalog
  • 167Human study recordsClinical trials and human studies
  • 45Public Study-at-a-Glance summariesSource-reviewed summaries available on the public site

Indexed records by source category

  • Human Studies & Clinical Data 167
  • Animal / Cell / Preclinical Data 100
  • Regulatory Documents & Official Trial Registries 112
  • Review Articles / Secondary Sources 66

Counts show how many records exist per source type, not evidence strength.

Browse the research

Three ways into the same evidence base: by compound, by individual study, or by research area.

By compound

Peptide Library

Compound profiles with evidence grade, mechanism context, regulatory status and the studies behind each one.47 research profilesOpen the libraryBy study

Study Database

A searchable index of human, preclinical, regulatory and review sources, filterable by evidence category, source type and year.445 indexed recordsSearch studiesBy research area

Explore by research area

Browse peptide research by area, evidence grade, and human-research availability.Explore peptides

Research areas in the library

How MitoCore presents evidence

MitoCore does not run studies or make treatment claims. It organizes what public sources report, shows where each finding comes from, and states plainly what has and has not been approved.

How MitoCore grades evidence

  1. Source-linked

    Study records link to the original publication, trial registry entry or regulatory document.

  2. Evidence graded by type

    Human, preclinical, regulatory and review sources are kept separate, and each profile carries an evidence grade.

  3. Approved vs. investigational

    What a regulator has approved is stated separately from what a given study investigated.

  4. Limitations stay visible

    Study-at-a-Glance summaries report limitations, safety findings and negative results alongside the headline outcome.

Study-at-a-Glance

Plain-language summaries of individual studies, each reviewed against its source. A sample across research areas — including studies that did not meet their goals.

Browse all studies

45 Study-at-a-Glance summaries are currently public.

  • HumanPhase 3RandomizedDouble-blind

    Tirzepatide · 2022

    Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

    In SURMOUNT-1, 2,539 adults with obesity or overweight and no diabetes took tirzepatide or placebo weekly for 72 weeks. Weight fell 15.0% to 20.9% on tirzepatide versus 3.1% on placebo. Stomach side effects were common.

    Source status: Clinical trial registry record · Peer-reviewed article · Abstract only — full text not reviewed · FDA / regulatory source

    Read the full summary for TirzepatideView in Study Database: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

  • HumanPhase 3RandomizedDouble-blind

    Angiotensin II · 2017

    Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3)

    ATHOS-3 tested angiotensin II in 321 adults whose blood pressure stayed too low despite strong vasopressor drugs. More people on it reached the blood-pressure goal at 3 hours (114 of 163 vs 37 of 158). The difference in deaths by day 28 was not statistically significant.

    Source status: Clinical trial registry record · Peer-reviewed article · Abstract only — full text not reviewed · FDA / regulatory source

    Read the full summary for Angiotensin IIView in Study Database: Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3)

  • HumanPhase 3RandomizedDouble-blind

    SS-31 · 2023

    The MMPOWER-3 Randomized Clinical Trial

    MMPOWER-3 did not meet its main goals. In 218 adults with primary mitochondrial myopathy, daily elamipretide did not improve 6-minute walking distance or fatigue over 24 weeks versus placebo, and the trial was ended.

    Source status: Clinical trial registry record · Peer-reviewed article · FDA / regulatory source

    Read the full summary for SS-31View in Study Database: The MMPOWER-3 Randomized Clinical Trial

Mechanisms and pathways

See how research connects peptides to biological targets, signaling pathways, and biological processes.

Pathway links are labelled by how well supported they are — direct, indirectly supported, inferred or uncertain — so an inferred relationship is never presented as an established one.

Explore mechanisms

How a pathway is shown

  1. Peptide
  2. Target
  3. Signaling
  4. Pathway
  5. Process

Relationship strength

  • Directly supported
  • Supported indirectly
  • Inferred from related evidence
  • Uncertain

Learn the science

Educational guides explain how peptides are made, tested, stored and studied. They are separate from the research database: Learn explains concepts; the database and profiles show what the studies report.

All Learn guides

Latest research

Recently added studies, regulatory developments and MitoCore research updates.

View all research news

Start with the evidence

Search the corpus, open a compound profile, or read the methodology behind the grades.

Explore ResearchRead the methodology

Stay Updated on Peptide Research

Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.

Interests (optional)